Follow The Filings

ATRC Atricure Inc.

Health Care, filed as ATRICURE INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 2 Owners
  • Max 3.2%
  • $25M
  • 1 add

In 2026 Q2 First Eagle Investment Management added to Atricure.

Who owns this now

Largest portfolio weights among holders, up to 3.2% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel 3.2%
  2. First Eagle Investment Manage... Add 0.01%

Who owns ATRC

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 3.2% Hold 597,431 $17M History
First Eagle Investment Management 0.01% Add +13.5% 297,643 $8.3M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ATRC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ATRC insider trades
  • None no insider bought on the open market
  • $3.5M sold by 7 insiders outside a trading plan
  • $880K sold by 1 insider under 10b5-1 plans
  1. Salvatore Privitera Chief Technical Officer
    Planned sale
    $271K 4,519 shares at $60.00 3.1% of stake
    Traded Sep 23 Filed Sep 24
    ↗
  2. Regina E Groves Director
    Sale
    $288K 5,313 shares at $54.22 13% of stake
    Traded Sep 11 Filed Sep 14
    ↗
  3. Salvatore Privitera Chief Technical Officer
    Planned sale
    $201K 3,657 shares at $55.00 2.4% of stake
    Traded Sep 8 Filed Sep 10
    ↗
  4. Salvatore Privitera Chief Technical Officer
    Planned sale
    $408K 7,763 shares at $52.50 4.9% of stake
    Traded Sep 2 Filed Sep 4
    ↗
  5. Karl S. Dahlquist Chief Legal Officer
    Sale
    $458K 9,370 shares at $48.89 9.7% of stake
    Traded Aug 24 Filed Aug 26
    ↗
  6. Maggie Yuen Director
    Sale
    $134K 3,500 shares at $38.42 20% of stake
    Traded Aug 5 Filed Aug 7
    ↗
  7. Karen Prange Director
    Sale
    $138K 3,564 shares at $38.80 14% of stake
    Traded Aug 5 Filed Aug 7
    ↗
  8. Vinayak Doraiswamy Chief Scientific Officer
    Sale
    $233K 6,000 shares at $38.88 6.5% of stake
    Traded Jul 28 Filed Jul 30
    ↗
  9. Justin J Noznesky Chief Mktg & Strategy Officer
    Sale
    $240K 6,182 shares at $38.80 5.8% of stake
    Traded Jul 29 Filed Jul 30
    ↗
  10. Sven Wehrwein Director
    Sale
    $946K 25,000 shares at $37.84 38% of stake
    Traded Jul 28 Filed Jul 30
    ↗
  11. Karen Prange Director
    Sale
    $86K 3,000 shares at $28.65 10% of stake
    Traded May 20 Filed May 22
    ↗
  12. Vinayak Doraiswamy Chief Scientific Officer
    Sale
    $141K 5,000 shares at $28.13 5.2% of stake
    Traded May 15 Filed May 18
    ↗
  13. Vinayak Doraiswamy Chief Scientific Officer
    Sale
    $149K 5,000 shares at $29.83 4.9% of stake
    Traded Mar 12 Filed Mar 16
    ↗
  14. Justin J Noznesky Chief Mktg & Strategy Officer
    Sale
    $193K 5,166 shares at $37.29 6.2% of stake
    Traded Nov 26, 2025 Filed Nov 26, 2025
    ↗
  15. Sven Wehrwein Director
    Sale
    $377K 10,000 shares at $37.66 23% of stake
    Traded Nov 24–25 Filed Nov 26, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 28 stock grants, 7 share withholdings for taxes, 6 gifts, and 4 option exercises.

Congress

2 members of Congress traded ATRC in the last three years: 4 buys and 2 sales. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Partial sale $1K–$15K Sep 29 filed Oct 12
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Aug 20 filed Sep 10
  3. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Mar 3 filed Apr 7
  4. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K May 6, 2025 filed Jun 6, 2025
  5. Josh Gottheimer D-NJ-5Joint Buy $1K–$15K Jul 19, 2024 filed Aug 15, 2024
  6. Josh Gottheimer D-NJ-5Joint Sell $1K–$15K Jun 18, 2024 filed Jul 9, 2024

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K/A 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $399.24M $465.31M $534.53M
Gross profit $300.37M $347.52M $400.78M
Gross margin * 75.2% 74.7% 75.0%
Net income -$30.44M -$44.7M -$11.45M
Net margin * -7.6% -9.6% -2.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $266.25M $267.83M $322.52M
Total non-current assets * $347.69M $341.5M $331.66M
Total assets $613.93M $609.33M $654.18M
Total current liabilities $74.57M $73.42M $81.52M
Total non-current liabilities * $73.2M $74.94M $80.72M
Total equity $466.17M $460.97M $491.94M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $4.48M $12.2M $57.33M
Cash from investing $21.82M $30.23M -$14.55M
Cash from financing -$0.032M -$3.6M $1.18M
Net change in cash $26.21M $38.41M $44.71M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf